Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma

Nguyen-Pham, Thanh-Nhan; Im, Chang-Min; Nguyen, Truc-Anh Thi; Lim, Mi-Seon; Hong, Chang Yee; Kim, Mi‐Hyun; Lee, Hyun Ju; Lee, Youn-Kyung; Cho, Duck; Ahn, Jae‐Sook; Yang, Deok‐Hwan; Kim, Yeo-Kyeoung; Chung, Ik‐Joo; Kim, Hyeoung-Joon; Lee, Je‐Jung

doi:10.1016/j.leukres.2011.03.032

Cited by 10 publications

(19 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, IL-12 added exogenously to the co-culture could significantly promote activation of the NK cells mediated by TLR7 and/ or TLR8. In line with other reports [32,33], the results suggested that type I IFN and IL-12 play important roles in the DC-induced NK cell activation. At the same time, we also detected the up-regulation of IL-15 and IL-18 that has been reported to be required in the activation of NK cells stimulated by DCs in the presence of TLR agonists [34,35].…”

Section: Discussionsupporting

confidence: 92%

TLR7/8 agonists promote NK–DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma

Zhou

Zhang

et al. 2015

Cancer Letters

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

TLR7/8 agonists promote NK–DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma

Zhou

Zhang

et al. 2015

Cancer Letters

View full text Add to dashboard Cite

“…Such helper activity of NK cells is at least partially mediated by the functional modulation of DCs. This phenomenon depended on the production of IFN-γ and TNF-α by activated NK cells [68] and was associated with enhanced tumor antigen cross-presentation and the induction of Th1 and CTL responses [69-71]. Recent data from our laboratory and other groups has demonstrated that such NK-DC interactions promote the subsequent induction of tumor-specific responses in CD4 + and CD8 + T cells, allowing NK cells to act as helper cells in the development of type-1 polarized DCs in responses against cancer [69-71].…”

Section: How Dc-based Vaccines In MM Can Be Improvedmentioning

confidence: 99%

Cellular immunotherapy using dendritic cells against multiple myeloma

Nguyen-Pham

Lee

et al. 2012

Korean J Hematol

Self Cite

View full text Add to dashboard Cite

Cellular therapy with dendritic cells (DCs) is emerging as a useful immunotherapeutic tool to treat multiple myeloma (MM). DC-based idiotype vaccination was recently suggested to induce idiotype-specific immune responses in MM patients. However, the clinical results so far have been largely disappointing, and the clinical effectiveness of such vaccinations in MM still needs to be demonstrated. DC-based therapies against MM may need to be boosted with other sources of tumor-associated antigens, and potent DCs should be recruited to increase the effectiveness of treatment. DCs with both high migratory capacity and high cytokine production are very important for effective DC-based cancer vaccination in order to induce high numbers of Th1-type CD4 + T cells and CD8 + cytotoxic T lymphocytes. The tumor microenvironment is also important in the regulation of tumor cell growth, proliferation, and the development of therapeutic resistance after treatment. In this review, we discuss how the efficacy of DC vaccination in MM can be improved. In addition, novel treatment strategies that target not only myeloma cells but also the tumor microenvironment are urgently needed to improve treatment outcomes.

show abstract

“…DCs that have been stimulated by NK cells are capable of priming potent cytotoxic T-lymphocytes (CTLs) through promotion of Th1 polarization. Accordingly, in the presence of toll-like receptor 3 (TLR3) agonists, type 1 interferon and IL-2, NK-stimulated DCs have been shown to induce myeloma-specific CTLs which could prove valuable in DCbased myeloma therapies (Nguyen-Pham et al, 2011). The latter may be limited however by innate cytotoxicity against autologous DCs in MM (Zheng et al, 2002).…”

Section: Other Nk Cell-based Immunotherapymentioning

confidence: 99%